Celldex Therapeutics, Inc. (CLDX) financial statements (2021 and earlier)

Company profile

Business Address 53 FRONTAGE ROAD
HAMPTON, NJ 08827
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1946494139190290
Cash and cash equivalents441124404272
Short-term investments151537099147218
Other undisclosed current assets325565
Total current assets:1986799145196295
Noncurrent Assets
Operating lease, right-of-use asset33
Property, plant and equipment446101311
Intangible assets, net (including goodwill)31494915917230
Goodwill   91919
Intangible assets, net (excluding goodwill)314949688121
Other noncurrent assets002221
Total noncurrent assets:38565717118843
TOTAL ASSETS:236123156316383338
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1088213026
Accounts payable111222
Accrued liabilities867192924
Debt12    
Other liabilities325754
Total current liabilities:141213283530
Noncurrent Liabilities
Long-term debt and lease obligation22    
Operating lease, liability22
Liabilities, other than long-term debt101619528317
Other liabilities101619528317
Total noncurrent liabilities:121719528317
Total liabilities:2629327911847
Stockholders' equity
Stockholders' equity attributable to parent20994124236265290
Common stock000000
Additional paid in capital1,2801,1051,0841,046982879
Accumulated other comprehensive income333332
Accumulated deficit(1,073)(1,013)(962)(813)(719)(591)
Total stockholders' equity:20994124236265290
TOTAL LIABILITIES AND EQUITY:236123156316383338

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues74101375
Cost of revenue (0)(60) (3)(1)
Cost of goods and services sold (0)(1)   
Gross profit:73(51)1344
Operating expenses(75)(58)(106)(135)(137)(134)
Other undisclosed operating income4  1  
Operating loss:(63)(55)(156)(122)(133)(130)
Loss from continuing operations before equity method investments, income taxes:(63)(55)(156)(122)(133)(130)
Other undisclosed income from continuing operations before income taxes2444  
Loss from continuing operations before income taxes:(61)(51)(152)(117)(133)(130)
Income tax benefit1 124  
Net loss attributable to parent:(60)(51)(151)(93)(133)(130)
Other undisclosed net income available to common stockholders, basic    42
Net loss available to common stockholders, diluted:(60)(51)(151)(93)(129)(127)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(60)(51)(151)(93)(133)(130)
Comprehensive loss:(60)(51)(151)(93)(133)(130)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00052
Comprehensive loss, net of tax, attributable to parent:(60)(51)(151)(93)(128)(127)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: